Benchmark Maintains Buy on Agilon Health, Raises Price Target to $13

Benzinga Newsdesk www.benzinga.com Positive 82.3%

Neg 0% Neu 0% Pos 82.3%

Benchmark analyst Bill Sutherland maintains Agilon Health (NYSE:AGL) with a Buy and raises the price target from $1.5 to $13.